Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01836523




Registration number
NCT01836523
Ethics application status
Date submitted
17/04/2013
Date registered
22/04/2013
Date last updated
6/03/2017

Titles & IDs
Public title
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Scientific title
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Secondary ID [1] 0 0
2012-003580-21
Secondary ID [2] 0 0
NN9211-3919
Universal Trial Number (UTN)
Trial acronym
ADJUNCT ONE™
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes 0 0
Diabetes Mellitus, Type 1 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo

Experimental: Liraglutide 0.6 mg + insulin -

Experimental: Liraglutide 1.2 mg + insulin -

Experimental: Liraglutide 1.8 mg + insulin -

Placebo comparator: Liraglutide placebo 0.6 mg + insulin -

Placebo comparator: Liraglutide placebo 1.2 mg + insulin -

Placebo comparator: Liraglutide placebo 1.8 mg + insulin -


Treatment: Drugs: liraglutide
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Treatment: Drugs: placebo
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Treatment: Drugs: liraglutide
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Treatment: Drugs: placebo
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Treatment: Drugs: liraglutide
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Treatment: Drugs: placebo
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Timepoint [1] 0 0
Week 0, week 52
Primary outcome [2] 0 0
Change From Baseline in Body Weight
Timepoint [2] 0 0
Week 0, week 52
Primary outcome [3] 0 0
Change From Baseline in Total Daily Insulin Dose
Timepoint [3] 0 0
Week 0, week 52
Secondary outcome [1] 0 0
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes
Timepoint [1] 0 0
Weeks 0-52

Eligibility
Key inclusion criteria
* - Informed consent obtained
* - Type 1 diabetes mellitus for 12 months or longer
* - Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump) treatment for 6 months or longer
* - Stable insulin treatment for the last 3 months prior to Screening, as judged and documented by the investigator
* - HbA1c 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive, (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))
* - Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, complete trial related questionnaires, diaries, self-monitoring of plasma glucose, self titration of insulin and attend all scheduled visits
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* - Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPP-4) inhibitors
* - Use of any medication, which in the investigator's opinion could interfere with the glycaemic control or affect the subject's safety.Premix insulin is not allowed
* - Known proliferative retinopathy or maculopathy requiring acute treatment
* - Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator
* - Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or above 100 mmHg for diastolic
* - History of acute or chronic pancreatitis
* - Screening calcitonin value equal to or above 50 ng/L
* - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)
* - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2015
Sample size
Target
Accrual to date
Final
1398
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Novo Nordisk Investigational Site - Broadmeadow
Recruitment hospital [2] 0 0
Novo Nordisk Investigational Site - Elizabeth Vale
Recruitment hospital [3] 0 0
Novo Nordisk Investigational Site - Keswick
Recruitment hospital [4] 0 0
Novo Nordisk Investigational Site - Melbourne
Recruitment hospital [5] 0 0
Novo Nordisk Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
2292 - Broadmeadow
Recruitment postcode(s) [2] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [3] 0 0
5035 - Keswick
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Vermont
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Caba
Country [29] 0 0
Argentina
State/province [29] 0 0
Capital Federal
Country [30] 0 0
Argentina
State/province [30] 0 0
Córdoba
Country [31] 0 0
Argentina
State/province [31] 0 0
Mendoza
Country [32] 0 0
Argentina
State/province [32] 0 0
Morón
Country [33] 0 0
Belgium
State/province [33] 0 0
Arlon
Country [34] 0 0
Belgium
State/province [34] 0 0
Edegem
Country [35] 0 0
Belgium
State/province [35] 0 0
Leuven
Country [36] 0 0
Belgium
State/province [36] 0 0
Liège
Country [37] 0 0
Canada
State/province [37] 0 0
Alberta
Country [38] 0 0
Canada
State/province [38] 0 0
Manitoba
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Finland
State/province [41] 0 0
Helsinki
Country [42] 0 0
Finland
State/province [42] 0 0
Pori
Country [43] 0 0
Finland
State/province [43] 0 0
Seinäjoki
Country [44] 0 0
Finland
State/province [44] 0 0
Tampere
Country [45] 0 0
Finland
State/province [45] 0 0
Turku
Country [46] 0 0
France
State/province [46] 0 0
Besancon
Country [47] 0 0
France
State/province [47] 0 0
Brest
Country [48] 0 0
France
State/province [48] 0 0
Caen
Country [49] 0 0
France
State/province [49] 0 0
Corbeil Essonnes
Country [50] 0 0
France
State/province [50] 0 0
DIJON cedex
Country [51] 0 0
France
State/province [51] 0 0
Le Creusot
Country [52] 0 0
France
State/province [52] 0 0
Narbonne
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
France
State/province [54] 0 0
Pointe à Pitre
Country [55] 0 0
France
State/province [55] 0 0
Poitiers
Country [56] 0 0
France
State/province [56] 0 0
Saint Herblain
Country [57] 0 0
France
State/province [57] 0 0
Saint Priest en Jarez
Country [58] 0 0
France
State/province [58] 0 0
Venissieux
Country [59] 0 0
Germany
State/province [59] 0 0
Eisenach
Country [60] 0 0
Germany
State/province [60] 0 0
Essen
Country [61] 0 0
Germany
State/province [61] 0 0
Hamburg
Country [62] 0 0
Germany
State/province [62] 0 0
Hohenmölsen
Country [63] 0 0
Germany
State/province [63] 0 0
Marburg
Country [64] 0 0
Germany
State/province [64] 0 0
Münster
Country [65] 0 0
Germany
State/province [65] 0 0
Pohlheim
Country [66] 0 0
Germany
State/province [66] 0 0
Rehlingen-Siersburg
Country [67] 0 0
Germany
State/province [67] 0 0
St. Ingbert
Country [68] 0 0
Ireland
State/province [68] 0 0
Dublin 9
Country [69] 0 0
Ireland
State/province [69] 0 0
Dublin
Country [70] 0 0
Ireland
State/province [70] 0 0
Galway
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Holon
Country [73] 0 0
Israel
State/province [73] 0 0
Jerusalem
Country [74] 0 0
Israel
State/province [74] 0 0
Petah Tikva
Country [75] 0 0
Israel
State/province [75] 0 0
Rishon Le Zion
Country [76] 0 0
Netherlands
State/province [76] 0 0
Amsterdam
Country [77] 0 0
Netherlands
State/province [77] 0 0
Den Haag
Country [78] 0 0
Netherlands
State/province [78] 0 0
Hoogeveen
Country [79] 0 0
Netherlands
State/province [79] 0 0
Leiden
Country [80] 0 0
Netherlands
State/province [80] 0 0
Nijmegen
Country [81] 0 0
Netherlands
State/province [81] 0 0
Rotterdam
Country [82] 0 0
Netherlands
State/province [82] 0 0
Venlo
Country [83] 0 0
Norway
State/province [83] 0 0
Bergen
Country [84] 0 0
Norway
State/province [84] 0 0
Gjettum
Country [85] 0 0
Norway
State/province [85] 0 0
Hamar
Country [86] 0 0
Norway
State/province [86] 0 0
Kongsvinger
Country [87] 0 0
Norway
State/province [87] 0 0
Stavanger
Country [88] 0 0
Poland
State/province [88] 0 0
Lublin
Country [89] 0 0
Poland
State/province [89] 0 0
Pulawy
Country [90] 0 0
Poland
State/province [90] 0 0
Warszawa
Country [91] 0 0
Poland
State/province [91] 0 0
Zabrze
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Kazan
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Penza
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Saratov
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Volgograd
Country [96] 0 0
Sweden
State/province [96] 0 0
Göteborg
Country [97] 0 0
Sweden
State/province [97] 0 0
Malmö
Country [98] 0 0
Sweden
State/province [98] 0 0
Stockholm
Country [99] 0 0
Ukraine
State/province [99] 0 0
Kharkov
Country [100] 0 0
Ukraine
State/province [100] 0 0
Kiev
Country [101] 0 0
Ukraine
State/province [101] 0 0
Poltava
Country [102] 0 0
Ukraine
State/province [102] 0 0
Zhytomir
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Blackburn
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Bristol
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Durham
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Edgbaston, Birmingham
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Edinburgh
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Middlesbrough
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Plymouth
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Southall
Country [111] 0 0
United Kingdom
State/province [111] 0 0
St Helens
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Stevenage

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
Trial website
https://clinicaltrials.gov/study/NCT01836523
Trial related presentations / publications
Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.
Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Erratum In: Diabetes Obes Metab. 2022 Nov;24(11):2280. doi: 10.1111/dom.14846.
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Registry (GCR, 1452)
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01836523